Cargando…

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

The REFLEX study (NCT00404352) established that subcutaneous (sc) interferon (IFN) β-1a reduced the risks of McDonald MS (2005 criteria) and clinically definite multiple sclerosis (CDMS) in patients with a first clinical demyelinating event suggestive of MS. The aim of this subgroup analysis was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freedman, Mark S., De Stefano, Nicola, Barkhof, Frederik, Polman, Chris H., Comi, Giancarlo, Uitdehaag, Bernard M. J., Casset-Semanaz, Florence, Hennessy, Brian, Lehr, Lorenz, Stubinski, Bettina, Jack, Dominic L., Kappos, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948518/ https://www.ncbi.nlm.nih.gov/pubmed/24413638 http://dx.doi.org/10.1007/s00415-013-7222-6

Ejemplares similares

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
por: Mattiesing, Rozemarijn M., et al.
Publicado: (2022)

The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study
por: Gentile, Giordano, et al.
Publicado: (2023)

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
por: Pincelli, Carlo, et al.
Publicado: (2006)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a
por: Vrenken, H., et al.
Publicado: (2023)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
por: Freedman, Mark S, et al.
Publicado: (2017)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
por: Munger, Kassandra L, et al.
Publicado: (2014)

N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry
por: Jasperse, Bas, et al.
Publicado: (2007)

Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a
por: Hupperts, Raymond, et al.
Publicado: (2019)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
por: Freedman, Mark S
Publicado: (2014)

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Immunoregulatory Effects of Subcutaneous Immunotherapy on Lymphocyte Subgroups and Cytokines in Children with Asthma
por: He, Yu-ting, et al.
Publicado: (2019)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Reflexes and conditioned reflexes
por: Geis, George L.
Publicado: (1965)

The Cough Reflex: The Janus of Respiratory Medicine
por: Sykes, Dominic L., et al.
Publicado: (2021)

Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient
por: Masuda, Hiroki, et al.
Publicado: (2017)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
por: Traboulsee, A, et al.
Publicado: (2017)

Reflex Colic and Reflex Diarrhœa
Publicado: (1909)

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
por: Kappos, Ludwig, et al.
Publicado: (2016)

Wired to Connect: The Autonomic Socioemotional Reflex Arc
por: Ludwig, Robert J., et al.
Publicado: (2022)

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study
por: O'Connor, Paul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_acm6sd8v398um1i9oj3hrgjbjp